RecruitingPhase 3NCT06836557
Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis
A Multicenter, Open Label, 3-Month Safety Study with Tradipitant in Patients with Idiopathic or Diabetic Gastroparesis
Sponsor
Vanda Pharmaceuticals
Enrollment
100 participants
Start Date
Jan 9, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
This is a multicenter, open label, 3-month safety study with tradipitant in patients with idiopathic and diabetic gastroparesis.
Eligibility
Min Age: 18 YearsMax Age: 70 Years
Inclusion Criteria4
- Diagnosed with gastroparesis
- Demonstrated delayed gastric emptying
- Presence of moderate to severe nausea
- Body Mass Index (BMI) of ≥18 and ≤40 kg/m2
Exclusion Criteria4
- Another active disorder or treatment which could explain or contribute to symptoms of gastroparesis
- A positive test for drugs of abuse at the screening or evaluation visits
- Pregnancy or nursing
- Evidence of uncontrolled blood glucose (including HbA1C >11% at screening or metabolic crisis in past 60 days)
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGTradipitant
BID
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06836557
Related Trials
Brain-Gut Yoga for Functional Dyspepsia and Gastroparesis (FD-GP)
NCT067324531 location
Gastroparesis Outcome Longitudinal Database Enrolled Numerically
NCT038762881 location
Growth Hormone for the Treatment of Gastroparesis
NCT068035892 locations
Domperidone in Treating Patients With Gastrointestinal Disorders
NCT016967341 location
Gastroparesis Registry 4
NCT058468026 locations